Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07729137 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction

Study acronym: EMERALD
StatusRecruiting
PhasePhase 2
SponsorEmmecell
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened
    • Trial sites expanded: 1 → 10 locations
    • Start date: Sep 2026 to Oct 2026
    • Eligibility criteria expanded, about 16 words
  2. Study description expanded, about 90 words
    • Secondary endpoints expanded, about 4 words
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate the safety and effectiveness of a single injection of EO2002 at one of two dose levels (150,000 or 500,000 magnetic human corneal endothelial cells \[mHCECs\]), compared with a placebo injection, in participants with corneal edema caused by corneal endothelial dysfunction.
Trial Details
NCT Number NCT07729137
Lead Sponsor Emmecell
Conditions
(from sponsor)		 Corneal Edema, Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy, Endothelial Corneal Dystrophy, Corneal Endothelial Decompensation, Corneal Endothelial Cell Loss, Corneal Endothelial Disorder +4 more
Related terms Corneal Edema, Corneal Endothelial Cell Loss, Corneal Endothelial Dystrophy 1, Corneal endothelial dystrophy type 2, Fuchs' Endothelial Dystrophy
Enrollment 121 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov